ASSESSING DNA METHYLATION OF ATG 5 AND MAPLC3AV1 GENE IN ORAL CANCER AND LEUKOPLAKIA
Not Applicable
- Conditions
- Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
- Registration Number
- CTRI/2023/10/058654
- Lead Sponsor
- DR.NISHANTHI.R
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
GROUP-A Clinically and histopathologically diagnosed oral carcinoma patients
GROUP-B-Clinically and histopathologically diagnosed Leukoplakia patients
group -C-Healthy individuals who undergo extraction
Exclusion Criteria
Patients diagnosed with epithelial tissue disorders.
Patients with no history of treated or untreated malignancies of any other system.
Patients not willing to participation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DNAMethylationofATG 5AND MAPLC3AV1 GENE IN ORAL CANCER AND LEUKOPLAKIA AT BASELINE TO ADVANCE STAGETimepoint: DNAMethylationofATG 5AND MAPLC3AV1 GENE IN ORAL CANCER AND LEUKOPLAKIA AT BASELINE TO ADVANCE STAGE
- Secondary Outcome Measures
Name Time Method In discovery of DNA Methylation enables us to better understanding of pathogenesis & will be crucial in successful strategies of cancer treatment at initial stages (at 1 year).Timepoint: In discovery of DNA Methylation enables us to better understanding of pathogenesis & will be crucial in successful strategies of cancer treatment at initial stages(at 1 year)